| Objective To compare the efficacy of combination regiments of topotecan/cisplatin and paclitaxel /carboplatin and cyclophosphamide/ cisplatin as first line chemotherapy in epithelial ovarian cancer. To observe the toxicity of the three regiments. To observe the overall survival rate in the three groups.Methods Total 94 eligible patients with pathologically verified stage Ⅱ ～ Ⅳ epithelial ovarian cancer were entered into the three groups of this clinical trial. (1) topotecan/cisplatin group (TP): 30 patients were treated with topotecan, 0.75mg/m~2/d, for 5 days, and cisplatin, 75mg/m~2, on day 1. (2)paclitaxel /carboplatin group (TC): 31 patients were treated with paclitaxel, 135mg/m~2, on day 1. and carboplatin, given to an area under the curve (AUC) of 5. on day 1. (3)cyclophosphamide/ cisplatin group (PC): 33 patients were treated with cyclophosphamide, 500mg/m~2, on day 1, cisplatin 75mg/m~2, on day 1. Cycles were repeated every 21～28 days. Efficacy of the three combination regiments were evaluated after 6～8 courses.Results (1) Efficacy: The overall response rate (ORR) in the TP group was 70%. Of the 30 patients, 8 achieved a complete response (CR) and 13 a partial response (PR). The ORR in the TC group was 80.6%. Of the 31 patients. 10 achieved a CR and 14 a PR. While the ORR in the PC group was 42.4%. Of the 33 patients. 5 achieved a CR and 9 a PR. There was no significant difference in clinical efficacy between TP group and TC group (P>0.05). But there was statistical significant difference between TP group and PC group (P<0.05). (2)Disease free survival (DFS): After median follow-up of 25 months, one-year disease free survival rate was 66.7% in TP group, 71.0% in TC group and 42.4% in PC group (P>0.05 ) . Two-year disease free survival rate was 56.7% in TP...
|
PDF Full Text Request